Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyBlue Cross Blue Shield NC mirikizumab IV Coverage …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Mirikizumab-mrkz (Omvoh) — Intravenous Infusion (Notification) Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for intravenous mirikizumab (Omvoh) for adults with moderately to severely active Crohn's disease or ulcerative colitis for Blue Cross Blue Shield North Carolina members.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyMirikizumab-mrkz (Omvoh) — Intravenous Infusion (Notification) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeRevised criteriaadded coding and dosing updates
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for IV mirikizumab induction dosing; authorization duration for induction is 90 days and dosing limits per indication must be followed.
    SourceLink
    POLICY UPDATE CHANGES

    For Crohn's disease: removed required trial and failure of conventional therapy and replaced allowance for severely active disease with required demonstration of moderately to severely active disease by documented symptoms plus evidence of inflammation OR significant extent/upper GI involvement OR corticosteroid-dependence/refractory to oral corticosteroids.

    For ulcerative colitis: removed required trial and failure of conventional therapy and replaced allowance for severely active disease with required demonstration of moderately to severely active disease by documented symptoms plus evidence of inflammation or high-risk disease OR corticosteroid-dependence/refractory to oral corticosteroids.

    Allowed patients currently established on a biologic or systemic immunomodulator (not the requested agent) who have had positive clinical benefit to be eligible under criteria when other conditions are met.

    Added HCPCS code J2267 and dosing / maximum unit references for IV induction dosing by indication (CD and UC).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2FDA-approved indications (CD, UC)
    18+Age requirement (years)
    3 dosesIV induction dosing schedule (weeks 0, 4, 8)
    90 daysInduction approval duration
    J2267Listed billing code for IV mirikizumab